title: Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
abstract: BACKGROUND
  Cancer stem cells are thought to represent the population of tumorigenic cells responsible for tumor development. The CD133 antigen has been described as a putative stem cell marker in malignant brain tumor that could identify such a tumorigenic population in a subset of glioblastoma. To date, the correlation between CD133 expression in primary glioblastoma and patient prognosis is not clearly established. To address this question we investigated the relationship between CD133 mRNA expression and patient outcome in a glioblastoma patient cohort.
  
  
  METHODS
  The quantitative expression of CD133 stem cell antigen mRNA using real-time QRT-PCR was assessed in a cohort of 48 consecutive primary glioblastoma patients treated by chemoradiation with temozolomide.
  
  
  RESULTS
  On multivariate survival analysis, high CD133 mRNA expression was a significant (P = 0.007) prognostic factor for adverse progression-free and overall survival independent of extent of resection (P = 0.012) and MGMT methylation status (P = 0.002). Patient age was also an independent prognosticator of overall survival (P = 0.037). Furthermore, according to the conjoined expression of CD133 mRNA and MGMT status, the patients were categorized into 3 groups with homogenous prognosis.
  
  
  CONCLUSIONS
  These findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen actually impacts the survival of GBM patients.
authors.affiliation: Service de Neurochirurgie, Hôpital de la Timone, Marseille, France. philippe.metellus@mail.ap-hm.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Metellus
authors.forename: Isabelle
authors.initials: I
authors.lastname: Nanni-Metellus
authors.forename: Christine
authors.initials: C
authors.lastname: Delfino
authors.forename: Carole
authors.initials: C
authors.lastname: Colin
authors.forename: Aurelie
authors.initials: A
authors.lastname: Tchogandjian
authors.forename: Bema
authors.initials: B
authors.lastname: Coulibaly
authors.forename: Frederic
authors.initials: F
authors.lastname: Fina
authors.forename: Anderson
authors.initials: A
authors.lastname: Loundou
authors.forename: Marylin
authors.initials: M
authors.lastname: Barrie
authors.forename: Olivier
authors.initials: O
authors.lastname: Chinot
authors.forename: L'houcine
authors.initials: L
authors.lastname: Ouafik
authors.forename: Dominique
authors.initials: D
authors.lastname: Figarella-Branger
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D059248:Chemoradiotherapy; D015331:Cohort Studies; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010455:Peptides / Q000235:genetics* / Q000378:metabolism; D011446:Prospective Studies; D012333:RNA, Messenger / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D012333:RNA, Messenger; D003606:Dacarbazine; D000077204:Temozolomide